President Donald Trump’s freeze on U.S. foreign aid has temporarily suspended key anti-narcotics programs in Mexico, impacting efforts to curb the flow of fentanyl into the U.S. The freeze affects all programs under the State Department’s Bureau of International Narcotics and Law Enforcement (INL), which trains Mexican authorities to dismantle clandestine fentanyl labs and intercept precursor chemicals.
INL initiatives, including drug-detecting canines that helped seize millions of fentanyl pills in 2023, have been put on hold. Former State Department official Dafna H. Rand criticized the freeze, stating it weakens the U.S.'s ability to combat the fentanyl crisis, which has claimed over 450,000 American lives in the past decade.
The freeze follows Trump’s "America First" policy, halting billions in foreign assistance worldwide. Despite Secretary of State Marco Rubio issuing waivers for humanitarian aid, most programs remain in limbo. Some officials suggest exemptions for foreign anti-narcotics programs are being considered, though no decision has been made on INL’s Mexico projects.
Trump has pledged to destroy Mexican cartels and threatened 25% tariffs on Mexico if it fails to curb fentanyl trafficking and illegal immigration. He has also pushed for designating cartels as terrorist organizations, expanding U.S. authority to target them. U.S. military surveillance of Mexican cartels has increased, raising concerns that Trump’s approach is shifting from cooperation with Mexico to unilateral action.
During his campaign, Trump called for military operations against cartels, signaling a tougher stance. While the administration’s next steps remain uncertain, the suspension of INL programs has stalled critical efforts to combat fentanyl at its source, complicating U.S.-Mexico cooperation on drug enforcement.


Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Laura Fernandez Set to Become Costa Rica’s Next President, Promising Sweeping Political Change
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
FDA Approves Mitapivat for Anemia in Thalassemia Patients
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains
UN Peacekeepers to Deploy Ceasefire Monitoring Team to Eastern Congo After Doha Talks
Israel Reopens Rafah Crossing, Offering Limited Relief to Gaza Patients Amid Ceasefire Efforts
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
DOJ Sues Virginia Over Failure to Provide Full Voter Registration Records
Syria Detains Group Over Rocket Attacks on Damascus Military Airport Amid Hezbollah Allegations
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties 



